Diabetes and inflammatory diseases: An overview from the perspective of Ca2+/3'-5'-cyclic adenosine monophosphate signaling

doi:10.4239/wjd.v12.i6.767

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7446)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

312

WORD

175

HTML

4269

Figures (1-2)

223

Tables (1-2)

271

Sum=5250

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

530

Download

673

Sum=1203

Publishing Process of This Article

Item

Count

Browse

330

Download

663

Sum=993

Jun 15, 2021 (publication date) through Sep 20, 2024

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Diabetes. Jun 15, 2021; 12(6): 767-779
Published online Jun 15, 2021. doi: 10.4239/wjd.v12.i6.767

Diabetes and inflammatory diseases: An overview from the perspective of Ca²⁺/3'-5'-cyclic adenosine monophosphate signaling

Leandro Bueno Bergantin

Leandro Bueno Bergantin, Department ofPharmacology, Universidade Federal de São Paulo, São Paulo 04039-032, Brazil

Author contributions: Bergantin LB is the sole author; Bergantin L participated in the whole process of the study.

Conflict-of-interest statement: The author declares no conflict of interest, financial or otherwise.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Leandro Bueno Bergantin, PhD, Professor, Department of Pharmacology, Universidade Federal de São Paulo, Rua Pedro de Toledo, 669–Vila Clementino, São Paulo 04039-032, Brazil. leanbio39@yahoo.com.br

Received: December 2, 2020
Peer-review started: December 2, 2020
First decision: December 24, 2020
Revised: December 29, 2020
Accepted: March 7, 2021
Article in press: March 7, 2021
Published online: June 15, 2021
Processing time: 183 Days and 23.3 Hours

Core Tip

Core Tip: There are several reviews in the literature on diabetes and inflammatory diseases. Nonetheless, to my knowledge, this is the first review which clearly discusses the role of Ca²⁺/3'-5'-cyclic adenosine monophosphate (cAMP) signaling in the link between diabetes and inflammatory diseases. This article also includes a timeline of the major events in Ca²⁺/cAMP signaling, and discusses recent reports on the role of Ca²⁺ channel blockers for preventing Ca²⁺ signaling disruption due to coronavirus disease 2019 (COVID-19), including the correlation between COVID-19 and diabetes.